We are making significant advances in how Crohn's Disease and other GI related diseases will be treated in the future. Our TargetTab™, 1 pill, 1 day philosophy is the cornerstone of how Crohn's patients will seek relief from their symptoms.
We are combining wireless technology with pharmaceutical drug delivery that is better for patient outcomes.
Our team of engineers completed the design and prototyping for TargetTab™. TargetTab™ is verified and validated for pre-clinical testing.
TargetTab™ successfully tested and validated in pre-clinical animal studies.
TargetTab™ is on the path towards human clinical studies.
In the following year TargetTab™ will be submitted for FDA approval.
TargetTab™ has passed successful pre-clinical animal studies and is moving towards human studies within the year.
TargetTab™ communicates with patients’ mobile devices with no onboard batteries and includes proprietary smart polymer technology for the actuation/release system.
TargetTab™ will give people the ability to precisely deliver medication in the right place at the right time, transforming medicine and personalizing delivery for patients.
TargetTab™ expands what is possible for the delivery of therapeutics. The patients can monitor the capsule and release it when and where they need it most.
TargetTab™ interfaces with custom and current wearable and monitoring technology to interact with Learning Artificial Intelligence (AI) Healthcare Systems and the Internet of Medical Things (IoMT).
Day by day, we keep pushing and making great progress. The pre-clinical animal study certainly was a large milestone. We'll have another milestone coming up this year with additional studies. 10 years from now, you'll walk into a pharmacy, most all tablets, capsules will have some type of electronic system. This is a paradigm shift. As the world is changing around us we continue to keep our eye on a steady path to commercialization.